PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization
Background Proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) effectively
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …
Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
BLK Chng, WMP Heng, YM Soon… - Proceedings of …, 2022 - journals.sagepub.com
Introduction PCSK9 inhibitors demonstrated their effectiveness in reducing low-density
lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains …
lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains …
Application of PCSK9 inhibitors in practice: part 2: the patient experience
TM Kaufman, BA Warden, J Minnier, JR Miles… - Circulation …, 2019 - Am Heart Assoc
PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) are set to revolutionize the
treatment of hypercholesterolemia in the management of atherosclerotic risk, but numerous …
treatment of hypercholesterolemia in the management of atherosclerotic risk, but numerous …
Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
JA Rymer, KE Mues, KL Monda… - Journal of the …, 2020 - Am Heart Assoc
Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK 9i) are used to
reduce low‐density lipoprotein (LDL) cholesterol. PCSK 9i use after initiation, as well as …
reduce low‐density lipoprotein (LDL) cholesterol. PCSK 9i use after initiation, as well as …
[HTML][HTML] PCSK9 inhibitors in clinical practice: delivering on the promise?
RM Stoekenbroek, ML Hartgers, R Rutte, DD de Wijer… - Atherosclerosis, 2018 - Elsevier
Background and aims In clinical trials, protein convertase subtilisin/kexin type 9 (PCSK9)
inhibitors robustly lowered LDL-cholesterol (LDL-c) and had a favorable tolerability and …
inhibitors robustly lowered LDL-cholesterol (LDL-c) and had a favorable tolerability and …
Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model
DR Donald, VW Reynolds, N Hall, J DeClercq… - Journal of Clinical …, 2022 - Elsevier
Background Nearly 40% of patients do not continue proprotein convertase subtilisin/kexin
type 9 inhibitor (PCSK9i) therapy after 6 months, despite their ability to lower low-density …
type 9 inhibitor (PCSK9i) therapy after 6 months, despite their ability to lower low-density …
[HTML][HTML] PCSK9 inhibitors revisited: effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
J Vicente-Valor, X García-González… - Biomedicine & …, 2022 - Elsevier
Introduction Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged
as a therapeutic option for patients with hypercholesterolemia who do not attain low-density …
as a therapeutic option for patients with hypercholesterolemia who do not attain low-density …
Effectiveness, safety, and adherence to treatment of proprotein convertase subtilisin/Kexin Type 9 inhibitors in real practice
M Gayoso-Rey, O Díaz-Trastoy, EY Romero-Ventosa… - Clinical Therapeutics, 2021 - Elsevier
Purpose To evaluate the effectiveness, adverse reactions, and adherence to treatment of
hypolipidemic inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9is) in a …
hypolipidemic inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9is) in a …
PCSK9 inhibitors in a German single-center clinical practice: real-world treatment of patients at high cardiovascular risk over 68 weeks
T Hollstein, U Kassner, T Grenkowitz… - American Journal of …, 2021 - Springer
Aims Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for
patients at high/very high cardiovascular risk who are inadequately treated with maximally …
patients at high/very high cardiovascular risk who are inadequately treated with maximally …
Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world …
M Saborowski, M Dölle, MP Manns, H Leitolf… - Cardiology …, 2018 - journals.viamedica.pl
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitors have shown
great potential in efficient lipid lowering to achieve low-density lipoprotein-cholesterol (LDL …
great potential in efficient lipid lowering to achieve low-density lipoprotein-cholesterol (LDL …